Retinopathy of prematurity: contribution of inflammatory and genetic factors

Mariza Fevereiro-Martins1,2,3 · Hercília Guimarães5 · Carlos Marques-Neves1,4 · Manuel Bicho1,2

Received: 16 July 2021 / Accepted: 16 February 2022
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

Abstract
Retinopathy of prematurity (ROP) is a retinal vasoproliferative disorder that represents an important cause of childhood visual impairment and blindness. Although oxidative stress has long been implicated in ROP etiology, other prenatal and perinatal factors are also involved. This review focuses on current research involving inflammation and genetic factors in the pathogenesis of ROP. Increasing evidence suggests that perinatal inflammation or infection contributes to ROP pathogenesis. Cytokines and chemokines with a fundamental role in inflammatory responses and that significantly contributing to angiogenesis are analyzed. Microglia cells, the retinal-resident macrophages, are crucial for retinal homeostasis, however, under sustained pathological stimuli release exaggerated amounts of inflammatory mediators and can promote pathological neovascularization. Current modulation of angiogenic cytokines, such as treatment with antibodies to vascular endothelial growth factor (anti-VEGF), has shown efficacy in the treatment of ocular neovascularization; however, some patients are refractory to anti-VEGF agents, suggesting that other angiogenic or anti-angiogenic cytokines need to be identified. Much evidence suggests that genetic factors contribute to the phenotypic variability of ROP. Several studies have implicated the involvement of candidate genes from different signaling pathways in the development of ROP. However, a genetic component with a major impact on ROP has not yet been discovered. Most studies have limitations and did not replicate results. Future research involving bioinformatics, genomics, and proteomics may contribute to finding more genes associated with ROP and may allow discovering better solutions in the management and treatment of ROP.

Keywords Retinopathy of prematurity · Inflammation · Polymorphism · Genetic · Angiogenesis · Preterm infant

Abbreviations
AA Arachidonic acid
ADAM “A” disintegrin and metalloproteinase
ANGs Angiopoietins
BDNF Brain-derived neurotrophic factor
bFGF Basic fibroblast growth factor
BH4 Tetrahydrobiopterin

BV Blood vessels
BW Birth weight
EC Endothelial cells
eNOS Endothelial nitric oxide synthase
ECM Extracellular matrix
EPAS1 Endothelial PAS Domain Protein 1
EPO Erythropoietin

1 Laboratório de Genética and Grupo Ecogenética e Saúde Humana, Instituto de Saúde Ambiental, Faculdade de Medicina, Universidade de Lisboa, Av. Professor Egas Moniz, Piso 1C, 1649-028 Lisboa, Portugal
2 Instituto de Investigação Científica Bento da Rocha Cabral, Calçada Bento da Rocha Cabral 14, 1250-012 Lisboa, Portugal
3 Departamento de Oftalmologia, Hospital Cuf Descobertas, Rua Mário Botas, 1998-018 Lisboa, Portugal
4 Centro de Estudos das Ciências da Visão, Faculdade de Medicina, Universidade de Lisboa, Av. Professor Egas Moniz, Piso 1C, 1649-028 Lisboa, Portugal
5 Departamento de Ginecologia-Obstetrícia e Pediatria, Faculdade de Medicina, Universidade do Porto, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal

Published online: 09 March 2022
Retinopathy of prematurity (ROP) is a retinal vasoproliferative disorder that affects preterm infants (PTI) and represents an important cause of blindness and childhood visual impairment [1] in developed and developing countries [2, 3].

The development of the retinal vascularization begins around 16 weeks of gestation, proceeds centrifugally from the optical disc to the peripheral retina, and is completed approximately at term [4]. For this reason, the retina of PTI is incompletely vascularized, with a peripheral avascular area that depends on the immaturity of the newborn infant [4, 5].

Clinical findings in PTI and studies in animal models of oxygen-induced retinopathy (OIR), of which the mouse OIR model (5 days of exposure to 75% oxygen after birth, followed by room air) is one of the most used [6], have shown that ROP has two phases (Fig. 1) [7]. The exposition of the immature retinal blood vessels (BV) to a relatively hyperoxic environment due to premature birth interrupts the vascular development [8]. This leads to microvascular retinal degeneration with an arrest in the vascularization of the peripheral retina (phase 1) [9]. The resulting retinal ischemia triggers the release of growth factors responsible for pathological angiogenesis (phase 2) [7, 10]. The new BV lead to the formation of a fibrovascular scar that may cause retinal detachment and vision loss [11]. It remains unclear why some PTI have a severe and rapidly progressive form of ROP, designated aggressive ROP (A-ROP) [12].

Retinopathy of prematurity is classified in five stages according to its severity [12]. In stage 1 a fine demarcation line is visible between the vascular and the avascular area of the retina [12]. This flat line can progress to a ridge that defines stage 2 [12]. These two first stages are considered initial or mild ROP and can regress spontaneously. In stage 3 there is pathological vessel proliferation over the ridge and into the vitreous, a feature of severe ROP [13]. The new abnormal vessels can bleed into the vitreous chamber, causing fibrosis and traction and thereby lead to a partial detachment of the retina that defines phase 4 [13]. This can evolve to stage 5, in which retina is totally detached [13].

In most studies over time the incidence of ROP is approximately 60% and of severe ROP (stages 3 to 5) is approximately 15% in PTI with birth weight (BW) of less than 1500 g [14, 15]. However, in a multicenter study conducted in the USA and Canada that included 7,483 with BW of less than 1501 g, the incidence of ROP was 43.1% and that of severe ROP was 12.4% [16] (Table 1). Severe ROP occurs mostly among PTI with birth weight less than 1251 g [16]. Globally, of the 14.9 million PTI in 2010, approximately 184,700 developed any stage of ROP, over 30,000 of whom became visually impaired as a consequence of ROP [17]. Sixty-five percent of the visually impaired due to ROP were born in middle-income regions [17].

Retinopathy of prematurity is considered a multifactorial disease that involves prenatal and postnatal factors [18]. Oxidative stress (OS) which can result from inflammation [19, 20] has long been implicated in the etiology of ROP [20, 21]. It is recognized that inflammatory processes can interfere with normal retinal vascularization and, more recently, are also considered important factors in the pathogenesis of ROP [20].

Genetic polymorphisms involve one of two or more sequence variants of a specific DNA sequence and occur with a population frequency of at least 1% [23]. Genetic
polymorphisms can influence the activity of encoded enzymes and the susceptibility to develop complications induced by reactive oxygen species (ROS) provided by genes involved in the regulation of OS [1, 22]. Studies have shown associations of genetic polymorphisms in genes involved in the pro-oxidant and pro-inflammatory response to premature birth and diseases related to OS in PTI [23].

Although ROP is strongly associated with extreme prematurity [24], environmental factors have also been implicated in the development of ROP, mainly high oxygen supplementation after birth and fluctuations in oxygenation [25, 26], but also nutrition [27], factors related to the causes of preterm birth [28], use of maternal medications [29], maternal smoking [30], altitude [31], length of day during early gestation [32], and assisted conception [33, 34]. These perinatal factors may alter gene expression through DNA acetylation and methylation, supporting the supposition that epigenetic modifications by external factors may affect gene expression and render PTI susceptible to severe ROP or PTI genetically prone to ROP not to develop retinopathy [35].

In addition to the contribution of environmental factors, a marked genetic predisposition to ROP is suggested from research based on the candidate gene approach, twin studies, experimental, and clinical studies. The observation that ROP in a subset of PTI progresses to a severe stage, while in others with similar clinical characteristics regresses spontaneously is a strong indication of the genetic contribution to the etiology of ROP [36, 37].

Identifying susceptibility factors for ROP and a better comprehension of its pathogenesis is determinant for its proper prevention and treatment. It may also help to clarify the pathophysiology of other pediatric and adult neovascular retinal diseases. This review focuses on current research that involves inflammation and genetic factors in the pathogenesis of ROP.

**The role of inflammation as a stress response: mediators of immune and inflammatory response in ROP**

Prenatal and postnatal systemic inflammation might predispose to ROP, and this sensitization effect may constitute a pre-stage of the disease [38]. Inflammatory stimuli such as chorioamnionitis [39] and neonatal bacteremia [40] have been suggested in several studies to be risk factors for ROP, possibly due to systemic inflammation [38]. Systemic inflammation in animal models has also been shown to disrupt the development of retinal BV and leads to aberrant retinal vascularization [41].
<table>
<thead>
<tr>
<th>Clinical studies</th>
<th>Study design and participants</th>
<th>Findings</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analyze ROP incidence and/or determine risk factors for the development of ROP</td>
<td>Multicenter Trial of Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) (1986–1987). 4099 PTI with BW &lt; 1251 g from the USA</td>
<td>65.8% of PTI developed some degree of ROP. ROP incidence was 81.6% for PTI with BW &lt; 1000 g. The incidence of ROP was independent of whether the newborn was male or female. An increased risk for the development of ROP was associated with younger gestational age, lower birth weights, white race, being born outside a study center nursery, and multiple birth</td>
<td>[95, 97, 110]</td>
</tr>
<tr>
<td>Analyze and compare the incidence of severe ROP between Caucasian and black PTI</td>
<td>Multicenter Trial of Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) (1986–1987). 4099 PTI with BW &lt; 1251 g from the USA</td>
<td>Severe ROP was more frequent in low-BW Caucasian PTI than in low-BW black PTI apparently at equivalent risk</td>
<td></td>
</tr>
<tr>
<td>To determine the ROP incidence in the Early Treatment for Retinopathy of Prematurity (ETROP) Study and compare the results with those obtained in the Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) Study</td>
<td>Multicenter prospective study (2000 to 2002) 6998 PTI with BW &lt; 1251 g from the USA</td>
<td>The incidence of ROP was 68% among PTI &lt; 1251 g. The overall incidences of ROP were like the Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) Study but there was more zone I ROP. Among PTI with ROP, more severe (pre-threshold) ROP occurred in 36.9% of PTI</td>
<td>[24]</td>
</tr>
<tr>
<td>Classify risk factors according to their contribution to the development or progression of ROP</td>
<td>Retrospective study (2010 to 2015) 324 PTI with GA &lt; 32 wk or BW &lt; 1501 g in Seoul</td>
<td>The incidence of ROP was 48.5%. Severe ROP occurred in 14.8% of all eyes and in 30.6% of eyes with ROP. Risk factors that regulate the development of ROP versus the progression of ROP were not identical</td>
<td>[15]</td>
</tr>
<tr>
<td>To find the incidence, beginning, and initial course of ROP in a representative cohort of PTI undergoing ROP screening</td>
<td>Retrospective study (2006 to 2011) 7483 PTI from 29 hospitals in the USA and Canada that performed serial ROP examinations</td>
<td>The incidence of ROP was 43.1%. Of all PTI, 12.4% developed severe ROP and 6.9% developed ROP requiring treatment. 98.1% of severe ROP cases occurred in PTI with a BW inferior to 1251 g</td>
<td>[16]</td>
</tr>
<tr>
<td>Analyze zygosity data from 63 monozygotic and 137 dizygotic twin pairs to estimate and determine genetic susceptibility to ROP</td>
<td>Retrospective study (1994 to 2004) 400 PTI with GA ≤ 32 wk from Sweden and the USA</td>
<td>70.1% of the variance in liability for ROP was due to genetic factors. In the mixed effects logistic regression analysis, the GA and the duration of supplemental oxygen were shown to be significant covariates for ROP</td>
<td>[91]</td>
</tr>
<tr>
<td>Analyze genetic susceptibility and the influence of different environmental risk factors on ROP development</td>
<td>Retrospective study (2000 to 2014) 257 PTI with GA ≤ 32 wk from Spain</td>
<td>Genetic factors accounted for 72.8% of the variability in the ROP stage, environmental risk factors 23.08%, and random factors 4.12%. The environmental variables associated with increased risk of ROP were number of days of tracheal intubation, postnatal weight gain, and development of sepsis</td>
<td>[92]</td>
</tr>
<tr>
<td>Find prenatal and perinatal risk factors for severe retinopathy (stage 3 or 4) ROP</td>
<td>Prospective study (1998 to 1999) 2105 PTI with GA &lt; 32 wk or BW &lt; 1500 g from Australia or New Zealand</td>
<td>The incidence of severe ROP showed differences according to maternal ethnicity. This study also confirmed that prematurity is the most important risk factor for ROP and identified low BW for GA and male gender as significant risk factors</td>
<td>[96]</td>
</tr>
<tr>
<td>Identify risk factors for ROP requiring treatment</td>
<td>Retrospective study (1997 to 2008) 6490 PTI with GA &lt; 32 wk from Denmark</td>
<td>Male gender was a statistically independent risk factor for ROP requiring treatment. New statistically independent risk factors for ROP requiring treatment were blood transfusion and mechanical ventilation</td>
<td>[108]</td>
</tr>
</tbody>
</table>
## Table 1 (continued)

### Clinical studies

<table>
<thead>
<tr>
<th>Objectives</th>
<th>Study design and participants</th>
<th>Findings</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Determine predictive factors for ROP requiring referral in the telemedicine approach</td>
<td>Multicenter retrospective study (2011 to 2013) 979 PTI with BW &lt; 1251 g from the USA</td>
<td>When controlling for prematurity and very low body weight, the presence of stage 2 ROP, pre-plus disease, retinal hemorrhage, and the need for ventilation at the time of the first study-related ophthalmological observation were strong independent predictors for ROP requiring referral in the telemedicine approach. Male gender was an independent predictor for ROP requiring referral in the telemedicine approach</td>
<td>[107]</td>
</tr>
<tr>
<td>Determine the incidence of ROP in the state of New York</td>
<td>Retrospective study (1996 to 2000) 15,691 Newborn infants with initial length of stay &gt; 28 days in a New York hospital</td>
<td>In the New York state, the overall incidence of any ROP among all newborn infants was 0.2%. In the study population of newborn infants with initial length of stay &gt; 28 days, the incidence of any ROP was 20.3% among newborns with a BW &lt; 1500 g and 27.3% among newborns with a BW &lt; 1200 g. The probability of ROP development was 24% lower in African American patients compared to newborns of other races, controlling for all other variables. Male gender or Hispanic ethnicity did not show a statistically significant association with the development of ROP</td>
<td>[111]</td>
</tr>
</tbody>
</table>

### Experimental studies

<table>
<thead>
<tr>
<th>Objectives</th>
<th>Study design</th>
<th>Findings</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investigate the incidence and severity of neovascularization in Brown Norway and Sprague Dawley rats in OIR and acidosis-induced retinopathy model for ROP</td>
<td>110 Brown Norway rats and 110 Sprague Dawley rats OIR model: 20 newborn Sprague Dawley rats and 20 newborn Brown Norway rats were submitted to OIR. 10 newborn SD rats and 10 newborn BN rats for control group Acidosis-induced retinopathy model: A first set of 40 newborn Sprague Dawley rats and 40 newborn Brown Norway rats were submitted to acidosis-induced retinopathy model. 20 newborn Sprague Dawley rats and 20 newborn Brown Norway rats for control group. A second set of 20 newborn Sprague Dawley rats and 20 newborn Brown Norway rats were submitted to acidosis-induced retinopathy model</td>
<td>The incidence and severity of neovascularization in OIR were significantly higher in Brown Norway than in Sprague Dawley rats. The findings in acidosis-induced retinopathy model were limited. In OIR, the greatest severity of neovascularization was associated with increased retinal VEGF mRNA in Brown Norway OIR rats</td>
<td>[94]</td>
</tr>
<tr>
<td>Examine the susceptibilities of different strains of rats to OIR</td>
<td>Six strains of rats were exposed to OIR</td>
<td>Marked and consistent differences regarding retinal vascularization and abnormalities in vascular morphology were observed in the response of different strains of inbred rats to cyclic hyperoxia, suggestive of a genetic component of OIR</td>
<td>[93]</td>
</tr>
<tr>
<td>Objectives</td>
<td>Study design</td>
<td>Findings</td>
<td>References</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Investigate the role of HIF-2α in pathological angiogenesis in mice</td>
<td>A targeting vector of the HIF-2α (HIF-1α-like factor) gene was designed. HIF-2α-knockout mice and wild-type mice were submitted to hyperoxia-normoxia treatment, used as a murine model of ROP</td>
<td>Hyperoxia-normoxia treatment induced neovascularization in wild-type mice, but not in HIF-2α-knockout mice. Removal of the inserted gene restored normal HIF-2α expression and retinal neovascularization. In parallel with HIF-2, EPO gene expression was significantly affected</td>
<td>[151]</td>
</tr>
<tr>
<td>To determine whether the retinal renin-angiotensin and VEGF systems affect vessel growth and whether agents that disrupt the renin-angiotensin system can prevent neovascularization related to retinal hypoxia in a rat model of ROP</td>
<td>In a model of ROP, the angiotensin-converting enzyme inhibitor lisinopril and the angiotensin type 1 receptor antagonist losartan were administered during the neovascularization period to neonatal transgenic (mRen-2) 27 rats that overexpress renin in tissues, and to Sprague Dawley rats</td>
<td>Retinal renin levels were higher with lisinopril and losartan and both prevented the growth of inner retinal blood vessels. In rats with ROP, the expression of VEGF and its type 2 receptor in proliferating blood vessels and in the inner retina were increased. Lisinopril reduced retinal VEGF and its type 2 receptor mRNA, whereas losartan had no effect</td>
<td>[172]</td>
</tr>
<tr>
<td>Assess the development of vascular dilation and tortuosity in the OIR mouse and analyze how targeted deletions of ADAM family members (A disintegrin and metalloproteinase) or intravitreal injection of bevacizumab influence the development of plus disease</td>
<td>Wild-type and Adam-knockout mice were exposed to OIR. Fundus imaging and fluorescein angiography were then analyzed</td>
<td>After exposure to OIR, wild-type and Adam-knockout mice developed retinal arterial tortuosity and venous dilation, two hallmarks of plus disease. The severity of plus disease correlates with increased proliferation of endothelial cells. Mice lacking Adam10 in endothelial cells and Adam8−/− and Adam9−/− mice developed relatively less plus disease compared to controls</td>
<td>[179]</td>
</tr>
<tr>
<td>Determine how ADAM17 inactivation in EC or in pericytes influence pathological retinal neovascularization, developmental angiogenesis, and heterotopic tumor growth</td>
<td>Mice lacking ADAM17 in EC (Adam17flox/flox/Tie2-Cre mice) and mice lacking ADAM17 in smooth muscle cells and pericytes (Adam17flox/flox/αsma-Cre mice) were exposed to OIR</td>
<td>ADAM17 inactivation did not affect developmental angiogenesis in any of the conditional knockout strains; however, pathological retinal neovascularization was decreased in Adam17flox/flox/Tie2-Cre mice, but not in Adam17flox/flox/αsma-Cre mice. Lack of ADAM17 in EC decreased ex vivo tube formation, and this can be restored by addition of ADAM17 HB-EGF substrate. It was also noted that ADAM17 is important for stimulating the response to VEGF-A in various receptors with known functions in endothelial cell biology</td>
<td>[178]</td>
</tr>
</tbody>
</table>

ADAM “A” disintegrin and metalloproteinase; BW birth weight; EC endothelial cells; EPO erythropoietin; GA gestational age; HIF Hypoxia-inducible factor; IGF-1 insulin-like growth factor 1; OIR oxygen-induced retinopathy; PTI preterm infants; Wk weeks
Cytokines

Cytokines are intercellular signaling polypeptides released by activated immune cells that are produced during inflammatory processes and in which they participate [42]. There is an overlap in molecular signaling between oxidative and inflammatory compounds, in which complex networks of signaling pathways link oxidative agents and pro-inflammatory cytokines [43] (Fig. 2). The vascular damage of the ischemic phase of proliferative retinopathies is followed by an inflammatory response with the production of pro-inflammatory cytokines, which cause an increase in vascular permeability, immune and other cells recruitment, activation and differentiation, apoptosis, and angiogenesis [44].

Angiogenesis is strongly orchestrated by a variety of angiogenic cytokines, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), transforming growth factor beta (TGF-β), and interleukin (IL)-1β [45, 46], and anti-angiogenic cytokines [46]. These cytokines contribute to the proliferation and migration of endothelial cells (EC), which is considered the hallmark of angiogenesis [46, 47].

One study reported significant correlations between levels of different cytokines in the first 3 weeks after birth and ROP development [48]. In an OIR model, the investigation of 94 selected genes known to be related to inflammation showed that many of them were upregulated in association with the clinical appearance of OIR [49]. The same authors analyzed the vitreous levels of 27 cytokines in PTI with stage 4 ROP and found higher levels of interleukin (IL) -6, IL-7, IL-10, IL-15, Eotaxin, bFGF, Granulocyte

![Fig. 2 Role of oxidative stress and inflammation in the pathogenesis of ROP. After preterm birth, premature infants are exposed to an excess of supplemental oxygen, leading to retinal vascular obliteration due to suppression of pro-angiogenic factors regulated by oxygen, oxidant stress, and excessive production of pro-inflammatory factors by damaged tissues. The vascular dropout results in hypoxia and HIF stabilization with subsequent production of growth factors. The microenvironment of retinal ischemia is characterized by microglial activation and release of many pro-angiogenic cytokines and chemokines, which cause pathological vasoproliferation. The major pro-inflammatory cytokines responsible for early responses are IL-1β, IL-6, and TNF-α. Other pro-inflammatory mediators include IL-17, IL-18, IL-23, IL-33, TGF-β, bFGF, and a variety of other cytokines and chemokines. These cytokines upregulate the synthesis of secondary inflammatory mediators and pro-inflammatory cytokines. IL-6 and TGF-β act as either pro-inflammatory or anti-inflammatory cytokines, under various circumstances. Proangiogenic cytokines, such as IL-1, TNF-α, and VEGF, directly or indirectly stimulate endothelial cells proliferation, migration, and tube formation. IL-1Ra, IL-4, IL-10, IL-11, and IL-13 are major anti-inflammatory cytokines. Except for IL-1Ra, anti-inflammatory cytokines also have at least some pro-inflammatory properties. In ischemic areas, the enhanced production of ROS can further increase the level of pro-inflammatory cytokines. ECM degradation by MMPs activated by inflammatory cytokines, growth factors, and ROS, as well as proteolytic enzymes released from MFs allows EC migration and growth factors recruitment to form new capillaries. AA arachidonic acid; ANGs angiopoietins; bFGF basic fibroblast growth factor; ECM extracellular matrix; EPO erythropoietin; ICAM-1 intercellular adhesion molecule-1; IGF-1 insulin-like growth factor 1; IL Interleukin; IL-1Ra Interleukin 1 receptor antagonist; I-TAC Interferon-inducible T-cell alpha chemotactant; MCP-1 monocyte chemotactic protein 1; MMPs matrix metalloproteinases; PC prostacyclin; PGs prostaglandins; PLA2 phospholipase A2; PLGF placental growth factor; PPARγ proliferator-activated receptor gamma; ROS reactive oxygen species; TGF-β transforming growth factor beta; TA thromboxane; TNF-α Tumor necrosis factor alpha; VEGF vascular endothelial growth factor; VEGFR vascular endothelial growth factor receptor.
colony-stimulating factor (G-CSF), interferon-gamma-inducible protein (IP) -10, and mainly, VEGF [50].

Molecules of the IL-1 family acting as the first line of defense against invasive pathogenic microorganisms and physical damage play an important role in inflammatory and immune responses. However, many cytokines in the IL-1 family, such as IL-1α, IL-1β, IL-18, IL-33, and IL-37, contribute significantly to angiogenesis [46, 51]. IL-1β, an important mediator of inflammation [46, 47], in ischemic conditions of the retina is markedly increased in recruited neutrophils, EC, and retinal glial cells [52, 53] and has been implicated in the development of vasoproliferative retinopathies [53]. It has been suggested that in the hypoxic neonatal retina, activated microglial cells produce increased amounts of IL-1β and tumor necrosis factor alpha (TNF-α) that can induce retinal ganglion cell death [54]. TNF-α is also known to contribute to the breakdown of the blood–retinal barrier [54, 55].

In an OIR model, it was shown that retinal microglia is induced to produce IL-1β, leading to microvascular injury by the release of semaphorin 3A (Sema3A) from adjacent neurons [53]. Inhibition of the IL-1 β receptor prevented microglial activation and Sema3A expression in the retina, resulting in a significant decrease in vaso-obliteration and in the subsequent pathological pre-retinal neovascularization [53]. In another OIR model, inhibition of the IL-1 β receptor preserved the choroid and prevented external neuroretinal abnormalities, suggesting IL-1 β as a potential therapeutic target in ROP [56].

A mouse model of premature birth, in which chorioamnionitis was induced with an injection of IL-1β in utero, revealed that IL-1β causes sustained eye inflammation accompanied by delayed development of the retinal BV and thinning of the choroid, with all deleterious effects being prevented by antenatal administration of IL-1 receptor antagonist (IL-1Ra) [57]. However, in a study with preterm infants (PTI), the levels of IL-1β in the vitreous were identical and below detectable levels in patients with ROP and in control patients [50].

Cytokines have pro- and anti-inflammatory properties and regulate the human immune response acting in conjunction with specific cytokine inhibitors and soluble cytokine receptors [58]. IL-1Ra, IL-4, IL-10, IL-11, and IL-13 are considered anti-inflammatory cytokines [58].

The IL-1Ra was found at significantly elevated levels in the vitreous and tears of PTI with ROP, along with increased levels of VEGF, complement component proteins, and metalloproteinase 9 [59], possibly as a compensatory mechanism to prevent angiogenic effects of IL-18 and IL-1β [60].

In vitro, the inflammatory response induced in microglial cells was markedly reduced by IL-10 which inhibited the expression of TNF-α, MIP-1α, and regulated on activation, normal T cell expressed and secreted (RANTES) [61]. However, in an OIR mouse model, hypoxia guided the behavior of the macrophage to a pro-angiogenic phenotype via IL-10-activated pathways, implicating IL-10 in promoting pathological angiogenesis [62].

IL-38 is a novel cytokine from the IL-1 family that shares high-sequence homology with IL-1Ra [46, 63] and lower homology with IL-1β and other IL-1 family proteins [46]. A recent study in the OIR mice found that administration of IL-38 may help prevent pathogenic neovascularization and inflammation, suggesting that IL-38 is an anti-angiogenic cytokine and may have therapeutic potential for angiogenesis-related diseases [46].

IL-18 is a pleiotropic pro-inflammatory cytokine with an immunoregulatory activity [48]. Studies have suggested that the association of IL-18 with ROP may be as an immunoregulator and modulator of angiogenesis [48], promoting the regression of pathological neovascularization instead of inhibiting its development [64]. IL-6 is known to be a strong inducer of the acute-phase protein response; however, it has both pro-inflammatory and anti-inflammatory properties [58]. Twenty-four hours after birth, elevated levels of IL-6 and TNF-α were observed in PTI who subsequently needed treatment for ROP [65].

Tetrahydrobiopterin (BH4) is a crucial cofactor in several metabolic processes, with a fundamental role in maintaining inflammatory and neurovascular homeostasis [66]. A deficiency in BH4 can produce the uncoupling of endothelial nitric oxide synthase (eNOS), causing a reduction in nitric oxide bioavailability and increased ROS production [66, 67]. BH4 is involved in retinal vascular damage induced by oxygen due to its reduction caused by hyperoxia, which can result in decreased eNOS activity and increased superoxide [66, 68].

Chemokines

Chemokines are a family of low-molecular weight peptides that induce the activation and migration of specific cells, especially immune cells, such as leukocytes and microglia, and are involved in the inflammatory responses [69, 70]. The participation of chemokines in angiogenesis, growth control, and hematopoiesis has also been demonstrated [69].

IL-8, the first chemokine to be characterized, plays important roles in both eye inflammation and pathological neovascularization [71]. In a study involving PTI with early-onset clinical sepsis, elevated plasma levels of IL-8 in the first days of life were associated with later development of ROP requiring treatment [72]. In another study, high concentrations of IL-8 during the first three weeks after premature birth were associated with an increased risk for pre-threshold ROP [73]. According to these results, in an OIR rat model,
an increased level of an IL-8 homolog was observed during the peak of pathological neovascularization [69].

Monocyte chemotactic protein 1 (MCP-1), one of the most produced and transitory chemokines during inflammation [74], is expressed by activated microglia of the neuroretina and simultaneously an attraction factor for various cells of the immune system, including macrophages/microglia [75]. MCP-1 was found to be significantly increased in umbilical cord blood from PTI who developed ROP compared to PTI who did not develop ROP [76].

Low concentrations of the chemokine RANTES in the blood [48, 77] and vitreous [50] have been found in PTI who have developed severe ROP, suggesting that RANTES may play a protective role. In agreement, high concentrations of RANTES have been associated with a lower risk of ROP [73].

The current modulation of well-known angiogenic cytokines such as anti-VEGF therapy demonstrated efficacy in ocular neovascularization [46, 78]. However, some patients are refractory to anti-VEGF agents, suggesting that other angiogenic or anti-angiogenic cytokines that contribute in a coordinated manner to angiogenesis need to be identified [46, 51].

**Microglia**

Microglia cells, the retinal-resident macrophages that provide neuroprotection against transient pathophysiological insults and play an important role in neuronal homeostasis, under sustained pathological stimuli become overactivated and release exaggerated amounts of inflammatory mediators that may promote tissue damage [79]. IL-1β, IL-6, TNF-α, interferon-gamma (IFN-γ), and TGF-β are produced by a variety of cell types, being macrophages and monocytes the most important sources at inflammatory sites [42].

The macrophage population residing in many tissues is mainly derived from the yolk sac and fetal liver; however, after tissue injury, inflammatory monocytes recruited from the bone marrow complement it [80, 81]. Recent studies have indicated that macrophages play different roles in the process of intraocular neovascularization (Fig. 3) [82]. Macrophages can be divided into at least two main phenotypes with different functions: pro-inflammatory M1 macrophages and anti-inflammatory M2 macrophages with a major role in resolving inflammation [82, 83]. After tissue hypoxia, it has been proved that cytokines are involved in the recruitment of monocytes and polarization of macrophages, as well as in angiogenesis [82, 84]. The inflammatory microenvironment leads the macrophages to M1 polarization in an initial phase [85]. The change in the microenvironment in the late inflammatory phase drives macrophages toward the M2 polarization [85].

The M1 phenotype can be polarized by lipopolysaccharide and IFN-γ, while other cytokines such as IL-4, IL-10, and IL-13 can induce M2 polarization [82, 86]. In the hypoxic microenvironment, it has been suggested that MCP-1 may play a role in the recruitment of monocytes to the vitreous and retina [82].

It is also increasingly clear that epigenetic modifiers can regulate the fate of macrophages [87]. Differentiation toward M1 or M2 polarization and inflammation in situ are regulated by defined microRNAs subsets [85, 88].

M1 macrophages are seen as phagocytic and pro-inflammatory, secreting large amounts of pro-inflammatory cytokines, such as IL-1β, IL-23, and proteases, reactive nitrogen and oxygen intermediates, and little amount of anti-inflammatory IL-10 [85].

M2 macrophages, instead of M1, have been reported to increase angiogenesis in vivo and highly express bFGF, insulin-like growth factor 1 (IGF-1), placental growth factor (PLGF), and MCP-1 [82, 83]. In the OIR model, the M2 phenotype was concentrated around neovascular tufts, promoting the development of retinal neovascularization [89].

Specific molecular targets associated with macrophages can be considered as a potential treatment in the future for retinal neovascularization; however, further studies are needed [82].

**Genetic contribution**

There is growing evidence that ROP is influenced by genetic predisposition, epigenetic regulation, and environmental factors [35, 90]. The fact that PTI of the same gestational age (GA) and exposed to identical environmental risk factors can develop ROP characterized by different degrees of severity strongly supports a genetic contribution to the etiopathogenesis of ROP [36, 37]. A study concluded that in PTI with extreme phenotypes, the known clinical risk factors were not significantly associated with the development of ROP, suggesting that other clinical, maternal, or genetic factors may predispose or protect from ROP [2].

The evidence of a genetic influence in ROP also comes from two studies with monozygotic and dizygotic twins that obtained an estimated heritability for ROP of 70% and 73%, respectively [91, 92] (Table 1).

In animal models of OIR, studies of different strains of rats observed differences in the avascular area of the retina and the expression of VEGF between the strains, these phenotypic differences also support the influence of a genetic factor [93, 94].
The influence of a genetic component in the disease was initially based on racial and regional risk profiles resulting from epidemiological studies [95, 96]. The CRYO-ROP study found that although ROP occurred with similar incidence rates in the Caucasian and black populations, severe ROP was less common in black PTI [95, 97]. This result was found in other later studies [2, 98], although one study found an opposite result, a higher incidence of ROP requiring treatment in black PTI than in Caucasian PTI [99]. Studies have found a higher risk of ROP in Asians and Alaskan natives than in Caucasians [100, 101]. One mechanism to explain some of the racial differences observed in ROP is polymorphisms of the β-blocker receptor. A polymorphism of the G protein-coupled 5 kinase receptor desensitizes β-adrenergic receptors causing resistance to noradrenergic stimuli. Retinal EC have β-adrenergic receptors and this theory of polymorphism is reinforced by reports showing an association of cutaneous hemangiomas with ROP, indicating possible common pathogenesis [102]. Cutaneous hemangiomas show a profound reduction with systemic β-blocker treatment [103, 104] and a β-blocker in eye drops, propranolol 0.2%, reduced the progression of ROP in a recent multicenter clinical trial, being promising in the treatment of ROP [105]. Some studies have reported that the incidence of ROP [106] or progression to severe stages [98, 107–109] is more frequent in males than in females. However, in other studies,
no difference was observed in the incidence of ROP by gender [110, 111].

**Wnt pathway**

There are several studies on genetic polymorphisms in genes of the canonical Wnt pathway (dependent on beta-catenin) in ROP (Table 2). Variants of genes in the Wnt pathway cause familial exudative vitreoretinopathy (FEVR) or Norrie disease, which are diseases of the retinal development with characteristics similar to ROP although occurring in full-term infants [36, 90, 112]. Both of these diseases are hereditary disorders and have in common dysgenesis of the retinal vessels with a variable breakdown of the blood–retinal barrier, often leading to exudative and tractional retinal detachment [112, 113]. Molecular genetic studies have identified four genes that cause FEVR (NDP, FZD4, LRP5, and TSPAN12), which when mutated cause X-linked, AD, and AR FEVR (also some sporadic cases) [36]. Norrie disease results from mutations in the NDP gene [114].

Several studies correlate variants in genes of the Wnt pathway associated with FEVR or Norrie disease with an increased risk of severe ROP, suggesting involvement of genes associated with the Wnt pathway at least in a low portion of patients with severe ROP [36, 112, 115]. An important limitation of these results is the difficulty in distinguishing between PTI with severe ROP and PTI with FEVR [36]. Due to overlapping phenotypes, ROP is generally differentiated from FEVR by premature birth and lack of family history [112]. However, an ambiguous birth history can confuse the diagnosis [112] and some authors proposed the designation of ROPER (ROP vs. FEVR) to more accurately classify these patients [116].

**Vascular endothelial growth factor**

VEGF-A plays a key role in physiological and pathological angiogenesis [117, 118]. Studies had implicated VEGF and VEGF receptor (VEGFR)-2 in ROP development [119] and the VEGFA-VEGFR system is the main target for antiangiogenic treatment [120].

In two studies of the VEGFA -634 polymorphism, the G allele had a higher frequency between PTI with ROP [121, 122]. However, another study reported a higher frequency of C allele in severe ROP [123] and other studies have not confirmed an association between this polymorphism and ROP [124, 125].

**VEGFA** gene $-460C > T$ and $+13553C > T$ polymorphisms have also been associated with ROP [123, 126]. Although $-460C > T$ has been included in other studies, it was not associated with ROP [125, 127].

The frequency of polymorphisms in the VEGFR-1 and -2 genes did not affect the development of ROP in two studies [125, 126].

**Nitric oxide and endothelial nitric oxide synthase**

The isoform of nitric oxide-producing enzymes fairly specific for EC, eNOS, has been found to play a notable role in angiogenesis and vasculogenesis [128, 129]. Functional polymorphisms of the eNOS gene affect the expression of eNOS [129] and have been reported to be associated with cardiovascular diseases [130] and diabetic retinopathy in type 1 diabetes [129, 131].

ROP was associated with single-nucleotide polymorphisms (SNPs) of the eNOS gene (T-786C [132, 133] and G894T [132]), but these results have not been replicated in other studies [129, 134].

**Neurotrophins and serotonin**

Neurotrophins (NTs) are members of a family of polypeptide growth factors that control several aspects related to the survival, differentiation, and function of neurons in the central and peripheral nervous systems and with important functions in non-neuronal cells [135, 136]. NTs family includes nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5) [137].

NTs bind to tropomyosin kinase (Trk) receptors, NGF with high affinity for TrkA receptor, BDNF for TrkB receptor, and NT-3 for TrkC, resulting in activation of signaling pathways, namely phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT), mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinase (ERK), and phospholipase C gamma (PLCγ)/protein kinase C (PKC) [138]. BDNF and NGF have been described as playing an important role in the process of angiogenesis [137]. In different cell models, both NGF and BDNF promote the proliferation, migration, differentiation, and survival of EC [139, 140]. Moreover, both have been shown to induce VEGF expression, thus also having an indirect angiogenic role [141, 142].

Studies have associated lower-serum BDNF concentrations in the first week of life in PTI with the development of severe ROP [48]. A large-scale study of candidate genes in a cohort of PTI found SNPs (rs7934165 and rs2049046) in intrinsic regions of the BDNF gene associated with severe ROP [143]. This result supports the line of thought that neurovascular connections play a role in the development of ROP [144].

Different studies have shown a close relationship between BDNF and glial cell line-derived neurotrophic factor (GDNF) with the serotonergic system in brain development.
## Table 2: Studies investigating genetic polymorphisms of candidate genes in ROP

<table>
<thead>
<tr>
<th>Gene</th>
<th>Genetic Polymorphism/ rs or base change</th>
<th>Sample</th>
<th>Findings</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ANG2</strong></td>
<td>−35G&gt;C</td>
<td>90 PTI with ROP requiring treatment (GA 28.5±2.4 wk, BW 1160±300 g), 110 PTI without ROP or with ROP stage 1 or 2 not requiring treatment (GA 30.1±2.9 wk, BW 1200±280 g) PTI with stage 4 or 5 ROP (GA 23–30 wk, BW 600–1300 g), normal adult controls (GA 34–40 wk, BW 2430–3960 g)</td>
<td>No significant association with ROP</td>
<td>[168]</td>
</tr>
<tr>
<td>Angiotensin</td>
<td>rs699</td>
<td>43 PTI with ROP, 299 PTI without ROP (PTI studied: GA 27.1±1.8 wk, BW 915±249 g)</td>
<td>No significant association with ROP</td>
<td>[134]</td>
</tr>
<tr>
<td>Angiotensin-converting enzyme</td>
<td>Angiotensin-converting enzyme gene insertion/deletion (I/D) polymorphism</td>
<td>53 PTI with spontaneously regressed ROP (mean GA 30.2 wk [25–32 wk], mean BW 1195 g [713-1500 g]), 21 PTI with stage 4 or 5 ROP (mean GA 30.1 wk [24–32 wk], mean BW 1165 g [700-1500 g]), 107 PTI without ROP (mean GA 30.5 wk [24–32 wk], mean BW 1210 g [710-1500 g])</td>
<td>A higher incidence of genotype II when ROP cases were analyzed collectively as a group. A significantly higher incidence of DD genotype in the stage 4 or 5 ROP compared to spontaneously regressed ROP cases</td>
<td>[173]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1209 PTI: 341 PTI with DD genotype (mean GA 29 wk [22.9–36 wk], mean BW 1083 g [430-1495 g]), 624 PTI with DI genotype (mean GA 28.9 wk [23–35.9 wk], mean BW 1075 g [340-1495 g]), 244 PTI with II genotype (mean GA 28.8 wk [22.1–34.7 wk], mean BW 1065 g [410-1500 g])</td>
<td>No significant association with ROP</td>
<td>[174]</td>
</tr>
<tr>
<td>Angiotensin receptor 1</td>
<td>rs427832</td>
<td>102 PTI with ROP (GA 26±2 wk, BW 884±337 g), 228 without ROP (GA 28±2 wk, BW 1192±389 g)</td>
<td>Associated with the development of ROP</td>
<td>[152]</td>
</tr>
<tr>
<td></td>
<td>rs5186</td>
<td>43 PTI with ROP, 299 PTI without ROP (PTI studied: GA 27.1±1.8 wk, BW 915±249 g)</td>
<td>No significant association with ROP</td>
<td>[134]</td>
</tr>
<tr>
<td>BDNF</td>
<td>rs7934165, rs2049046</td>
<td>126 PTI with ROP requiring treatment (GA 24.5±1.2 wk, BW 697±125.0 g), 467 PTI with ROP not requiring treatment (GA 25.7±1.7 wk, BW 758±133.0 g), 264 PTI without ROP (GA 27.1±1.9 wk, BW 823.6±126.0 g)</td>
<td>The two intronic single nucleotide polymorphisms (SNPs) were associated with threshold ROP</td>
<td>[143]</td>
</tr>
<tr>
<td></td>
<td>rs7934165</td>
<td>140 PTI with ROP requiring treatment, 1257 PTI with ROP not requiring treatment or without ROP</td>
<td>A meta-analysis showed an association with severe ROP</td>
<td>[143]</td>
</tr>
<tr>
<td>Complement factor H</td>
<td>rs52985</td>
<td>102 PTI with ROP (GA 26±2 wk, BW 884±337G), 228 without ROP (GA 28±2 wk, BW 1192±389G)</td>
<td>An increment in the number of T alleles was associated with protection against ROP</td>
<td>[152]</td>
</tr>
<tr>
<td>Gene</td>
<td>Genetic Polymorphism/ rs or base change</td>
<td>Sample</td>
<td>Findings</td>
<td>References</td>
</tr>
<tr>
<td>-------------</td>
<td>----------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>rs800292</td>
<td></td>
<td>102 PTI with ROP (GA 26 ± 2 wk, BW 884 ± 337G), 228 without ROP (GA 28 ± 2 wk, BW 1192 ± 389G)</td>
<td>An increment in the number of T alleles was associated with protection against ROP</td>
<td>[152]</td>
</tr>
<tr>
<td>eNOS</td>
<td>rs2070744 (-786T &gt; C)</td>
<td>19 PTI with stage 4/5 ROP, 34 full-term normal adult controls</td>
<td>The frequency of the C allele was significantly elevated in ROP</td>
<td>[133]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>15 PTI with ROP, 131 PTI without ROP</td>
<td>The frequency of the C allele was significantly elevated in PTI with ROP</td>
<td>[132]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>43 PTI with ROP, 299 PTI without ROP (PTI studied: GA 27.1 ± 1.8 wk, BW 915 ± 249 g)</td>
<td>No significant association with ROP</td>
<td>[134]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>105 PTI with ROP requiring treatment (GA 28.4 ± 2.5 wk, BW 1150 ± 360 g), 127 PTI with stage 1 or 2 ROP (GA 30.5 ± 3.5 wk, BW 1300 ± 400 g)</td>
<td>No significant association with ROP</td>
<td>[129]</td>
</tr>
<tr>
<td></td>
<td>rs1799983 (894G&gt;T)</td>
<td>15 PTI with ROP, 131 PTI without ROP</td>
<td>The frequency of the T allele was significantly higher in PTI with ROP</td>
<td>[132]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>43 PTI with ROP, 299 PTI without ROP (PTI studied: GA 27.1 ± 1.8 wk, BW 915 ± 249 g)</td>
<td>No significant association with ROP</td>
<td>[134]</td>
</tr>
<tr>
<td>EPAS1</td>
<td>rs1868085</td>
<td>102 PTI with ROP (GA 26 ± 2 wk, BW 884 ± 337G), 228 without ROP (GA 28 ± 2 wk, BW 1192 ± 389G)</td>
<td>The frequency of the A allele was significantly higher in PTI with ROP</td>
<td>[152]</td>
</tr>
<tr>
<td>FZD4 (Frizzled 4, Wnt pathway)</td>
<td>c.97 C &gt; T; c.502 C &gt; T</td>
<td>93 ROP, 98 Full-term infants (controls)</td>
<td>c.97 C &gt; T; c.502 C &gt; T double missense mutation was present in 7 of 93 PTI with ROP (7.5%)</td>
<td>[112]</td>
</tr>
<tr>
<td></td>
<td>c.205 C &gt; T /rs80358282, c.380 G &gt; A/ rs184709254, c.313A &gt; G* (exon 2), c.40_49del* (exon 1)</td>
<td>53 advanced ROP (mean GA 25.1 [22–29 wk], mean BW 769.2 g [420-1244 g])</td>
<td>3 different nonsynonymous DNA variants in the coding region in 4 patients</td>
<td>[180]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9 atypical ROP cases (mean GA 33,78 wk [28–36 wk], mean BW 2324.44 g [1050-3500 g])</td>
<td>1 nonsynonymous and 1 frameshift DNA variant in 2 patients</td>
<td>[115]</td>
</tr>
<tr>
<td>HMOX-1</td>
<td>rs3074372</td>
<td>43 PTI with ROP, 299 PTI without ROP (PTI studied: GA 27.1 ± 1.8 wk, BW 915 ± 249 g)</td>
<td>No significant association with ROP</td>
<td>[134]</td>
</tr>
<tr>
<td>IGF-1 receptor</td>
<td>c.3174G &gt; A</td>
<td>108 PTI with ROP requiring treatment, 120 PTI with ROP stage 1 or 2 not requiring treatment, 164 full-term newborn controls</td>
<td>No significant association with ROP</td>
<td>[158]</td>
</tr>
<tr>
<td>Gene</td>
<td>Genetic Polymorphism/ rs or base change</td>
<td>Sample</td>
<td>Findings</td>
<td>References</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>----------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>52 PTI with stage 4 or 5 ROP (mean GA 26 wk [23–30 wk], mean BW 882 g [600–1300 g]), 33 full-term normal adult controls</td>
<td>No significant association with ROP</td>
<td>[157]</td>
</tr>
<tr>
<td><strong>IL-1β</strong></td>
<td>+ 3953C &gt; T</td>
<td>31 PTI with stage 1 or 2 ROP (mean GA 28 wk [24–31 wk]), 13 PTI with stage 3 ROP (mean GA 24 wk [23–26 wk]), 29 PTI without ROP (mean GA 31 wk [28–31 wk])</td>
<td>No significant association with ROP</td>
<td>[169]</td>
</tr>
<tr>
<td></td>
<td>− 1082G &gt; A</td>
<td>31 PTI with stage 1 or 2 ROP (mean GA 28 wk [24–31 wk]), 13 PTI with stage 3 ROP (mean GA 24 wk [23–26 wk]), 29 PTI without ROP (mean GA 31 wk [28–31 wk])</td>
<td>No significant association with ROP</td>
<td>[169]</td>
</tr>
<tr>
<td><strong>LRP5 (LDL receptor related protein 5, Wnt pathway)</strong></td>
<td>rs143924910 (c.3656 G &gt; A), c.4148 A &gt; C, rs141407040 (c.4619 C &gt; T)</td>
<td>53 advanced ROP (mean GA 25.1 [22–29 wk], mean BW 769.2 g [420–1244 g])</td>
<td>3 different nonsynonymous DNA variants in the coding region in 3 patients</td>
<td>[180]</td>
</tr>
<tr>
<td></td>
<td>c.2447A &gt; C* (exon 11), c.2431A &gt; G (exon 11), c.1434G &gt; A (exon 7)</td>
<td>9 atypical ROP cases (mean GA 33.78 wk [28–36 wk], mean BW 2324.44 g [1050–3500 g])</td>
<td>2 different nonsynonymous and 1 stop-gain DNA variants in 3 patients</td>
<td>[115]</td>
</tr>
<tr>
<td><strong>NDP (ND protein, Wnt pathway)</strong></td>
<td>Sequencing of all 3 exons and untranslated regions (UTR)</td>
<td>143 subjects of different ethnic backgrounds: 54 severe ROP (stage3 or worse) (mean GA 25.5 wk [23–32 wk], mean BW 773 g [367–1440 g], 36 mild or no ROP (mean GA 27.7 wk [24–34 wk], mean BW 968 g [650–1360 g]), 31 normal parents, 22 wild type (normal) controls</td>
<td>Genetic polymorphisms in the <strong>NDP</strong> gene were present in 6 of 54 (11%) PTI with severe ROP</td>
<td>[181]</td>
</tr>
<tr>
<td></td>
<td>Direct sequencing of the coding regions and a noncoding exon c.181C &gt; A* (exon 3), c.134 T &gt; G* (exon 2), c.134 T &gt; A* (exon 2)</td>
<td>53 advanced ROP (mean GA 25.1 [22–29 wk], mean BW 769.2 g [420–1244 g])</td>
<td>No sequence changes with pathogenic significance were identified</td>
<td>[180]</td>
</tr>
<tr>
<td></td>
<td>c.597C &gt; A, c.110C &gt; G</td>
<td>9 atypical ROP cases (mean GA 33.78 wk [28–36 wk], mean BW 2324.44 g [1050–3500 g])</td>
<td>3 different nonsynonymous DNA variants in 3 patients</td>
<td>[115]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>95 PTI with ROP, 115 PTI without ROP (PTI studied: mean GA 30.7 wk [26–36 wk], mean BW 1267 g [800–1500 g])</td>
<td>The AA genotype of the 597C &gt; A polymorphism was significantly associated with advanced ROP cases (83.3%) compared to spontaneous ROP regression cases (0%) and the normal controls (10.4%) (p &lt; 0.0001). No significant association between 110C &gt; G polymorphism and ROP</td>
<td>[182]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>16 PTI with ROP (mean GA 26.2 wk [23–30 wk], mean BW 882 g [601–1500 g]), 50 unrelated healthy control subjects</td>
<td>Missense mutations (R121W and L108P) observed in four patients. No statistical analysis</td>
<td>[183]</td>
</tr>
<tr>
<td><strong>TSPAN12 (tetraspanin 1, Wnt pathway)</strong></td>
<td>Direct sequencing of the coding regions and a noncoding exon c.194C &gt; T (exon 4)</td>
<td>53 advanced ROP (mean GA 25.1 [22–29 wk], mean BW 769.2 g [420–1244 g])</td>
<td>No sequence changes with pathogenic significance were identified</td>
<td>[180]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9 atypical ROP cases (mean GA 33.78 wk [28–36 wk], mean BW 2324.44 g [1050–3500 g])</td>
<td>1 nonsynonymous DNA variant in 1 Chinese patient</td>
<td>[115]</td>
</tr>
<tr>
<td>Gene</td>
<td>Genetic Polymorphism/ rs or base change</td>
<td>Sample</td>
<td>Findings</td>
<td>References</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>VEGFA</td>
<td>rs2010963 (−634G &gt; C, +405G &gt; C)</td>
<td>62 ROP (mean GA 32 wk [28–34 wk], mean BW 1400 g [1000–2110 g]), 40 no ROP PTI (mean GA 33 wk [29–35 wk], mean BW 1640 g [1009–2800 g])</td>
<td>G allele was significantly associated with ROP</td>
<td>[122]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>91 PTI with ROP requiring treatment (mean GA 25 wk [23–30 wk], mean BW 779 g [440–1185 g]), 97 PTI without ROP requiring treatment (mean GA 26 wk [23–32 wk], mean BW 920 g [448–2302 g])</td>
<td>G allele was more frequent in PTI with threshold ROP. Homozygotes for the G allele, related to increased VEGF production, were twice as likely to progress to threshold ROP</td>
<td>[121]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>86 PTI with ROP requiring treatment (GA 28.5 ± 2.0 wk, BW 1160 ± 300 g), 115 PTI without ROP requiring treatment (GA 29.2 ± 2.9 wk, BW 1200 ± 270 g)</td>
<td>Prevalence of C allele was higher in the treated PTI than in the untreated PTI (0.30 versus 0.41)</td>
<td>[123]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>42 PTI with ROP requiring treatment (BW 1097.5 ± 264.3 g, GA 28.2 ± 2.4 wk), 50 PTI with regressed ROP (BW 1253.0 ± 212.2 g, GA 29.7 ± 2.0 wk), 31 PTI without ROP (BW 1345.6 ± 225.9 g)</td>
<td>No significant association with ROP</td>
<td>[125]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>724 PTI with advanced ROP (stages 4 and 5) (BW 1349.3 ± 83.0 g, GA 30.1 ± 2.57), 878 PTI without ROP (BW 1360.3 ± 73.8 g, GA 31.1 ± 1.93 wk)</td>
<td>No significant association with ROP</td>
<td>[124]</td>
</tr>
<tr>
<td></td>
<td>rs833061 (−460C &gt; T)</td>
<td>86 PTI with ROP requiring treatment (GA 28.5 ± 2.0 wk, BW 1160 ± 300 g), 115 PTI without ROP requiring treatment (GA 29.2 ± 2.9 wk, BW 1200 ± 270 g)</td>
<td>Higher prevalence of −460TT / +405CC haplotype in the treated PTI than in the untreated PTI (13 of 86 versus 1 of 115)</td>
<td>[123]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>42 PTI with ROP requiring treatment (BW 1097.5 ± 264.3 g, GA 28.2 ± 2.4 wk), 50 PTI with regressed ROP (BW 1253.0 ± 212.2 g, GA 29.7 ± 2.0 wk), 31 PTI without ROP (BW 1345.6 ± 225.9 g)</td>
<td>No significant association with ROP</td>
<td>[125]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>61 PTI with stage 4/5 ROP (mean BW 882 g [600–1300 g], mean GA 26 wk [23–30 wk]), 61 full-term normal adult controls (BW 2430–3960 g, GA 34–40 wk)</td>
<td>No significant association with ROP</td>
<td>[127]</td>
</tr>
<tr>
<td></td>
<td>+13553C &gt; T</td>
<td>127 PTI with ROP (mean BW 944 g [378–2168 g], mean GA 27 wk [22–33 wk]), 77 PTI without ROP (mean BW 1596 g [692–2400 g], mean GA 32 wk [28–34 wk])</td>
<td>The TT genotype was significantly associated with non-severe ROP</td>
<td>[126]</td>
</tr>
</tbody>
</table>
Table 2 (continued)

<table>
<thead>
<tr>
<th>Gene</th>
<th>Genetic Polymorphism/ rs or base change</th>
<th>Sample</th>
<th>Findings</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs3025039 (+936C&gt;T)</td>
<td>62 ROP (mean GA 32 wk [28–34 wk], mean BW 1400 g [1000-2110 g]), 40 no ROP PTI (mean GA 33 wk [29–35 wk], mean BW 1640 g [1009-2800 g])</td>
<td>No significant association with ROP</td>
<td>[122]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>91 PTI with ROP requiring treatment (mean GA 25 wk [23–30 wk], mean BW 779 g [440-1185 g]), 97 PTI without ROP requiring treatment (mean GA 26 wk [23–32 wk], mean BW 920 g [448-2302 g])</td>
<td>No significant association with progression to threshold ROP</td>
<td>[121]</td>
<td></td>
</tr>
<tr>
<td>VEGFR-1 (Flt-1)</td>
<td>c. + 6724 (TG) 13–23 dinucleotide repeat</td>
<td>127 PTI with ROP (mean BW 944 g [378–2168 g], mean GA 27 wk [22–33 wk]), 77 PTI without ROP (mean BW 1596 g [692–2400 g], mean GA 32 wk [28–34 wk])</td>
<td>No significant association with ROP</td>
<td>[126]</td>
</tr>
<tr>
<td>VEGFR-2 (KDR)</td>
<td>+ 32 G &gt; A</td>
<td>42 PTI with ROP requiring treatment (BW 1097.5 ± 264.3 g, GA 28.2 ± 2.4 wk), 50 PTI with regressed ROP (BW 1253.0 ± 212.2 g, GA 29.7 ± 2.0 wk), 31 PTI without ROP (BW 1345.6 ± 225.9 g)</td>
<td>No significant association with ROP</td>
<td>[125]</td>
</tr>
<tr>
<td></td>
<td>g. + 4422(AC) 11–14 dinucleotide repeat</td>
<td>127 PTI with ROP (mean BW 944 g [378–2168 g], mean GA 27 wk [22–33 wk]), 77 PTI without ROP (mean BW 1596 g [692–2400 g], mean GA 32 wk [28–34 wk])</td>
<td>No significant association with ROP</td>
<td>[126]</td>
</tr>
<tr>
<td>Toll-like receptor-4 (TLR-4)</td>
<td>Asp299Gly</td>
<td>31 PTI with stage 1 or 2 ROP (mean GA 28 wk [24–31 wk]), 13 PTI with stage 3 ROP (mean GA 24 wk [23–26 wk]), 29 PTI without ROP (mean GA 31 wk [28–31 wk])</td>
<td>No significant association with ROP</td>
<td>[169]</td>
</tr>
<tr>
<td>TNF-α</td>
<td>− 308G &gt; A</td>
<td>31 PTI with stage 1 or 2 ROP (mean GA 28 wk [24–31 wk]), 13 PTI with stage 3 ROP (mean GA 24 wk [23–26 wk]), 29 PTI without ROP (mean GA 31 wk [28–31 wk])</td>
<td>No significant association with ROP</td>
<td>[169]</td>
</tr>
</tbody>
</table>

ANG angiopoietin; BDNF brain-derived neurotrophic factor; BW birth weight; eNOS endothelial nitric oxide synthase; EPAS1 endothelial PAS domain protein 1; GA gestational age; HMOX-1 heme oxygenase 1; IGF-1 insulin-like growth factor 1; IL interleukin; ROP retinopathy of prematurity; TNF-α tumor necrosis factor alpha; VEGF vascular endothelial growth factor; VEGFR vascular endothelial growth factor receptor; Wk weeks
and neuroplasticity [145, 146]. The synthesis and release of the neurotransmitter serotonin in the retina, and the existence of several types of serotonin receptors expressed in the retina, support its retinal neuromodulatory role [147]. Several data show that serotonin is implicated in retinal physiology and pathophysiology and photoreceptor survival; however, retinal signaling pathways activated by serotonin receptors have been little investigated to date [147].

**Hypoxia-inducible factor**

Hypoxia-responsive genes, such as VEGF and erythropoietin (EPO), are regulated mainly through hypoxia-inducible factor (HIF) [148], a heterodimeric transcription factor consisting of two subunits, HIF-1-alpha (or HIF-2-alpha and HIF3-alpha, their analogs) and HIF1-beta (also known as ARNT) [149]. During hypoxia, the HIF-1α level increases and it binds to HIF-1β in the nucleus to trigger the transcription of genes involved in angiogenesis and adaptation of cells to hypoxia [149].

Endothelial PAS Domain Protein 1 (EPAS1), also called HIF-2α, has high homology to HIF-1α and, like HIF-1α, EPAS1 is stabilized during hypoxia and forms a heterodimer with the ARNT translocator and transactivates the VEGF promoter [150]. In addition, this heterodimer complex has also been shown to transactivate Fli-1, which encodes VEGFR-1 [150].

In a study with a hyperoxia/normoxia treatment, using a murine model of ROP, HIF-2α-knockdown mice showed no evidence of retinal neovascularization when compared to wild-type mice [151]. The expression of EPO mRNA was also significantly decreased when compared to control mice [151]. A candidate gene study in PTI found an association between EPAS1 and the development of severe ROP [152]. It is possible that polymorphisms in the EPAS1 gene in PTI predispose to increased expression of angiogenic factors, such as VEGF and EPO [152].

**Erythropoietin**

EPO is an oxygen-regulated growth factor [44] and also an important angiogenic factor, its production being regulated by HIF [149]. EPO plays an important role in both the first and second phases of ROP [153]. A candidate gene study investigated the influence of an EPO polymorphism in the development of ROP, but no statistical significance was observed [152].

**Insulin-like growth factor 1**

IGF-1 is a growth factor supplied by the placenta and amniotic fluid that is crucial for fetal development, including healthy retinal angiogenesis [153]. It has been reported that it is also essential for postnatal vascular eye development and that a prolonged period of low levels of IGF-1 can predict the development of ROP and other diseases related to prematurity [154]. In patients with a genetic defect in the production of IGF-1, a reduction in retinal vascularization was observed, which has not been restored after the administration of IGF-1 [155].

Because the level of IGF-1 is determined by the IGF-1 receptor [156], it is possible that the most prevalent **IGF-1 receptor** polymorphism (c.3174G > A), which exhibits low levels of free plasma IGF-1, has a role in ROP [36]. However, the association of this polymorphism with the risk of advanced ROP has not been proven by studies in different populations [157, 158].

**Angiopoietins**

Angiopoietins (ANGs) are growth factors that regulate physiological and pathological neovascularization, specifically in association with VEGF [159, 160]. Although ANG-1 and ANG-2 bind to the Tie2 tyrosine kinase receptor, ANG-2 is a functional ANG-1 antagonist [161, 162]. ANG-1 contributes to the maintenance of vascular integrity [163], while ANG-2 stimulates neovascularization [164] and is upregulated by VEGF and hypoxia [165, 166].

The influence of the ANG-2 (−35G > C) gene polymorphism on ROP was investigated in two studies; however, no significance was reported [167, 168].

**Mediators of immune and inflammatory response**

Studies involving PTI have demonstrated the presence of multiple and complex associations of polymorphisms that occur in genes involved in the pro-inflammatory and pro-oxidant response with premature birth and the occurrence of SO diseases complicating prematurity [1, 23].

Regarding the association with ROP, one study suggested an increased risk of ROP progression with the presence of SNPs from the **IL-10**, **IL-1β**, and **TNF-α** genes, without changing the risk with an SNP of the **Toll-like receptor-4 (TLR-4)** gene, although none of these trends reached formal statistical significance [169].

**Heme oxygenase 1**

Heme oxygenase 1 (HMOX-1) is an enzyme that breaks down heme into iron ions, carbon monoxide, and biliverdin [134]. HMOX-1 products perform important physiological functions in the vascular system, related to the protection of the endothelium through a cytoprotective, promitogenic, and anti-inflammatory action [170].

The effectiveness of this enzyme is affected by repeated polymorphisms in the HMOX-1 gene promoter [170].
Despite this, no significant association was found between HMOX-1 and ROP in a candidate gene study [134].

**Renin–angiotensin system**

It has been shown that the renin–angiotensin system may influence the early stages of retinal vasculization [171] and retinal neovascularization was prevented by blocking the renin–angiotensin system in a rat model of ROP [172].

Angiotensin-converting enzyme gene polymorphism has been associated with ROP in the population of Kuwait [173], but not in another population [174].

A study of Angiotensin gene polymorphism found no association with ROP [134], while studies on the angiotensin receptor 1 gene found an association with the development of ROP [152] or found no association [134].

**Matrix metalloproteinases**

Matrix metalloproteinases (MMPs) are endopeptidases that hydrolyze the extracellular matrix (ECM) [175] and play an important role in inflammatory responses and angiogenesis among other various biological processes [176]. “A” disintegrin and metalloproteinase (ADAM) is also a family of enzymes involved in the degradation of components of the ECM [177].

Based on studies in animal models of OIR, some subtypes of the ADAM family have been suggested to be implicated in the ROP pathogenesis [178, 179]. Genetic studies in humans are needed to assess the influence of ECM, metalloproteinases, and the ADAM family on the pathogenesis of ROP.

**Other studies**

Apart from the studies described involving factors related to the pathogenesis of ROP, a large study mentioned above identified candidate genes with an unknown relationship with ROP, such as the complement factor H gene [152].

From the above, several evidences suggest a genetic contribution to ROP; however, it is not yet clear which genes or genetic polymorphisms are significantly associated with the development and progression of ROP. Many of the ROP candidate gene studies have limitations, essentially small sample size, non-replicable, or conflicting results from several studies, the latter of which may be at least in part, due to differences in neonatal care and clinical characterization in different countries or populations. In some studies, it may also be difficult to separate the contribution of genetic factors associated with ROP from those associated with prematurity itself.

Epigenetic studies on ROP have not been found in the literature, which could be an important contribution to the emergence of new methods for the treatment of this pathology. Future studies involving next-generation sequencing and genome-wide association, integrated with metabolomics and proteomics, may provide a better understanding of the genetic risk factors and pathophysiology of ROP and contribute to finding new solutions in the management and treatment of ROP.

**Expected clinical applicability of studies on genetics and inflammatory pathways in ROP**

The search for biomarkers to detect PTI with increased risk of developing ROP allowed the identification of potential indicators involved in inflammatory and angiogenic pathways. Circulating and genetic biomarkers can be incorporated into models to predict the risk of developing ROP. A risk analysis system that includes biomarkers and clinical risk factors can help neonatologists and ophthalmologists identify high-risk PTI. This may allow the development of more adequate follow-up strategies depending on the risk level of the PTI and reduce the number of ROP screening tests for those at lower risk.

A better understanding of the genetic contribution to the pathogenesis of ROP may also help to find new targets that lead to the development of therapeutic approaches that are more effective and less harmful than current ones. In addition, knowledge of the influence of genetic polymorphisms on phenotypic biomarkers (biochemical and cellular) can contribute to defining the ROP phase and, thus, choosing the most appropriate therapeutic approach over time.

Furthermore, a deeper knowledge of the molecular and genetic mechanisms involved in ROP may help to better understand and treat other oxidative stress diseases associated with prematurity with which ROP shares etiopathogenic factors.

Many molecules and related signaling pathways suspected to be involved in the pathogenesis of ROP are common to other pediatric and adult ischemic retinopathies. Thus, a deeper comprehension of molecular mechanisms in ROP may provide important insights to other retinal neovascular pathologies.

**Conclusion**

Several pieces of evidence suggest that the pathogenesis of ROP begins in utero. Perinatal inflammation and genetic factors may contribute to the development and progression of ROP.

Studies have implicated the involvement of factors linked to the inflammatory process, such as leukocytes, monocytes, macrophages, cytokines, chemokines, and growth factors, in
angiogenesis and pathological vascular development of ROP. Cytokines are also involved in monocyte recruitment and macrophage polarization. Macrophages may be recruited by long-term pathological neovascularization, but they can also promote pathological neovascularization.

Several studies have found genetic polymorphisms in candidate genes associated with ROP or severe ROP. Many pathways and their signaling molecules have been studied due to their connection with the pathogenesis of ROP. Associations were found between genes involved in the WNT signaling pathway, the VEGFA gene and the eNOS gene, and the development of ROP. A large multicenter study found polymorphisms in the BDNF gene associated with severe ROP.

Although multiple genes have been implicated in several investigations, a genetic component with a major impact on ROP has not yet been discovered. Several of these studies have not replicated findings mainly because of limitations in aspects such as sample size, non-replicable or conflicting results, and differences in neonatal care or inclusion criteria. The knowledge of such a genetic component would possibly allow the identification of possible targets to improve the screening and treatment of ROP.

New technologies involving bioinformatics, genomics, and proteomics may contribute to find genes or pathways associated with ROP and help in the future to find better solutions in the management and treatment of ROP.

Acknowledgments Special thanks to Ana Carolina Santos for her support in this work.

Author contributions The first draft of the manuscript was written by Mariza Fevereiro-Martins. Mariza Fevereiro-Martins and Manuel Bicho had the idea for the article. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding This work was supported by the Laboratório de Genética and the Instituto de Saúde Ambiental (ISAMB) of the Faculdade de Medicina of Universidade de Lisboa and the Instituto de Investigação Científica Bento da Rocha Cabral. The writing of the manuscript was also supported by funds from Fundação para a Ciência e a Tecnologia to ISAMB (ref. UIDB/04295/2020 and UIDP/04295/2020).

Data availability Not applicable.

Declarations

Conflict of interest The authors report no conflicts of interest.

References


32. Chan RV, Yonekawa Y, Morrison MA, Sun G, Wong RK, Per-}


34. Chan RV, Yonekawa Y, Morrison MA, Sun G, Wong RK, Per-}


50. Sato T, Kusaka S, Shimojo H, Fujikado T (2009) Simultaneous analysis of vitreous levels of 27 cytokines in eyes with retinopa-}


52. Chan RV, Yonekawa Y, Morrison MA, Sun G, Wong RK, Per-}

53. Chan RV, Yonekawa Y, Morrison MA, Sun G, Wong RK, Per-}

54. Chan RV, Yonekawa Y, Morrison MA, Sun G, Wong RK, Per-}

55. Chan RV, Yonekawa Y, Morrison MA, Sun G, Wong RK, Per-}

56. Chan RV, Yonekawa Y, Morrison MA, Sun G, Wong RK, Per-}

57. Chan RV, Yonekawa Y, Morrison MA, Sun G, Wong RK, Per-}
55. Luna JD, Chan CC, Derevjanik NL, Huang M, Yoshida M, Yabuuchi K, Honda Y, Hangai M, Yoshimura N, Yoshida M, Yabuuchi K, Honda Y
Molecular and Cellular Biochemistry


Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.